No Data
Stan V. Smith Trust Reported 6% Stake in Maia Biotechnology in 13D Filing
Stan V. Smith Trust Reported 6% Stake in Maia Biotechnology in 13D Filing
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.ECMOHO Limited (NASDAQ:MOHO) jumped 146.1% to settle at $0.4085 on above
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Gainers Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.Kaspien Holdings Inc. (NASDAQ:KSPN) gained 112.4% to $5.48.Eargo, Inc. (NASDAQ:EAR) sh
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
Gainers Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.Eargo, Inc. (NASDAQ:EAR) shares rose 148% to $1.74 in pre-market
Insider Buy: Maia Biotechnology
07:09 AM EDT, 08/03/2022 (MT Newswires) -- Stan Smith, Director, on August 01, 2022, executed a purchase for 200,000 shares in Maia Biotechnology (MAIA) for $1,000,000. Following the Form 4 filing wit
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Gainers MMTec, Inc. (NASDAQ:MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks.Applied DNA Sciences, Inc. (NASDAQ:APDN) surged 296.9% to settle at $2.80
Maia Biotechnology Receives FDA Orphan Drug Designation For THIO For The Treatment Of Small-Cell Lung Cancer
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the U.S.
MAIA Biotechnology raises $10M from public offering
U.S. clinical stage company MAIA Biotechnology, Inc. has closed its initial public offering of 2,000,000 shares of the company’s common stock at a public offering price of $5.00 per share.
MAIA Biotechnology: Proceeds From IPO Were $10M Prior to Deducting Underwriting Discounts, Commissions
MAIA Biotechnology: Proceeds From IPO Were $10M Prior to Deducting Underwriting Discounts, Commissions
MAIA Biotechnology Offering of 2M Shares Priced at $5 Each >MAIA
MAIA Biotechnology Offering of 2M Shares Priced at $5 Each >MAIA
Loading...